GP-1447, an inhibitor of aldose reductase, prevents the progression of diabetic cataract in rats

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 6, 2012, Pages 866-872

  Kawakubo, Ken ^a   Mori, Asami ^a   Sakamoto, Kenji ^a   Nakahara, Tsutomu ^a   Ishii, Kunio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Aldose reductase; Cataract; Diabetes; Hyperglycemia; Sorbitol

Indexed keywords

3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYL ACETIC ACID; 3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYLACETIC ACID; ALDOSE REDUCTASE INHIBITOR; GLUCOSE; POLYOL; SORBITOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; LENS; MALE; NONHUMAN; OUTCOME ASSESSMENT; RAT; RETINA; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; TREATMENT DURATION;

EID: 84861891098     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.866     Document Type: Article

References (38)

1. Jarrett RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet, 2, 1009-1012 (1976).
2. Klein BE, Klein R, Moss SE. Prevalence of cataracts in a population- based study of persons with diabetes mellitus. Ophthalmology, 92, 1191-1196 (1985).
3. Swamy-Mruthinti S, Shaw SM, Zhao HR, Green K, Abraham EC. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr. Eye Res., 18, 423-429 (1999).
4. Wormstone IM. Posterior capsule opacification: a cell biological perspective. Exp. Eye Res., 74, 337-347 (2002).
5. Kinoshita JH, Kador PF, Catiles M. Aldose reductase in diabetic cataracts. JAMA, 246, 257-261 (1981).
6. Kador PF, Akagi Y, Kinoshita JH. The effect of aldose reductase and its inhibition on sugar cataract formation. Metabolism, 35 (Suppl. 1), s15-s19 (1986).
7. Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, Abe N, Fukushima K, Matsuura A. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpn. J. Pharmacol., 73, 133-144 (1997).
8. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J., 13, 23-30 (1999).
9. Banditelli S, Boldrini E, Vilardo PG, Cecconi I, Cappiello M, Dal Monte M, Marini I, Del Corso A, Mura U. A new approach against sugar cataract through aldose reductase inhibitors. Exp. Eye Res., 69, 533-538 (1999).
10. Kubo E, Miyoshi N, Fukuda M, Akagi Y. Cataract formation through the polyol pathway is associated with free radical production. Exp. Eye Res., 68, 457-464 (1999).
11. Reddy AB, Tammali R, Mishra R, Srivastava S, Srivastava SK, Ramana KV. Aldose reductase deficiency protects sugar-induced lens opacification in rats. Chem. Biol. Interact., 191, 346-350 (2011).
12. Lyons TJ, Silvestri G, Dunn JA, Dyer DG, Baynes JW. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes, 40, 1010-1015 (1991).
13. Duhaiman AS. Glycation of human lens proteins from diabetic and (nondiabetic) senile cataract patients. Glycoconj. J., 12, 618-621 (1995).
14. Ihm SH, Yoo HJ, Park SW, Ihm J. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism, 48, 1141-1145 (1999).
15. Spector A. Review: Oxidative stress and disease. J. Ocul. Pharmacol. Ther., 16, 193-201 (2000).
16. Boscia F, Grattagliano I, Vendemiale G, Micelli-Ferrari T, Altomare E. Protein oxidation and lens opacity in humans. Invest. Ophthalmol. Vis. Sci., 41, 2461-2465 (2000).
17. Ozmen B, Ozmen D, Erkin E, Güner I, Habif S, Bayindir O. Lens superoxide dismutase and catalase activities in diabetic cataract. Clin. Biochem., 35, 69-72 (2002).
18. 2+ exchanger during cataractogenesis in diabetic rats. J. Diabetes Complications, 18, 177-182 (2004).
19. Duncan G, Bushell AR. Ion analyses of human cataractous lenses. Exp. Eye Res., 20, 223-230 (1975).
20. Pierce GN, Afzal N, Kroeger EA, Lockwood MK, Kutryk MJ, Eckhert CD, Dhalla NS. Cataract formation is prevented by administration of verapamil to diabetic rats. Endocrinology, 125, 730-735 (1989).
21. Hightower KR, Riley MV, McCready J. Regional distribution of calcium in alloxan diabetic rabbit lens. Curr. Eye Res., 8, 517-521 (1989).
22. Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, Ohkubo Y, Notsu Y, Yamaguchi I. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism, 40, 77-87 (1991).
23. Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, Obrosova IG. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int. J. Mol. Med., 21, 667-676 (2008).
24. Kametaka S, Kasahara T, Ueo M, Takenaka M, Saito M, Sakamoto K, Nakahara T, Ishii K. A novel high resolution in vivo digital imaging system for the evaluation of experimental cataract in diabetic rats. J. Pharmacol. Sci., 106, 144-151 (2008).
25. Matsumoto T, Ono Y, Kuromiya A, Toyosawa K, Ueda Y, Bril V. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats. J. Pharmacol. Sci., 107, 340-348 (2008).
26. Kametaka S, Kasahara T, Ueo M, Takenaka M, Saito M, Sakamoto K, Nakahara T, Ishii K. Effect of nifedipine on severe experimental cataract in diabetic rats. J. Pharmacol. Sci., 106, 651-658 (2008).
27. Chylack LT Jr, Leske MC, Sperduto R, Khu P, McCarthy D. Lens Opacities Classification System. Arch. Ophthalmol., 106, 330-334 (1988).
28. Leske MC, Chylack LT Jr, Sperduto R, Khu P, Wu SY, McCarthy D. Evaluation of a Lens Opacities Classification System. Arch. Ophthalmol., 106, 327-329 (1988).
29. Mori A, Saigo O, Sakamoto K, Nakahara T, Ishii K. Hyperglycemia impairs acetylcholine-induced vasodilation of retinal arterioles through polyol pathway-independent mechanisms in rats. J. Pharmacol. Sci., 112, 336-342 (2010).
30. Patterson JW. A review of glucose transport in the lens. Invest. Ophthalmol., 4, 667-679 (1965).
31. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev., 26, 380-392 (2005).
32. Kinoshita JH. Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture. Am. J. Ophthalmol., 102, 685-692 (1986).
33. Burg MB, Kador PF. Sorbitol, osmoregulation, and the complications of diabetes. J. Clin. Invest., 81, 635-640 (1988).
34. Kyselova Z, Stefek M, Bauer V. Pharmacological prevention of diabetic cataract. J. Diabetes Complications, 18, 129-140 (2004).
35. Obrosova IG, Chung SS, Kador PF. Diabetic cataracts: mechanisms and management. Diabetes Metab. Res. Rev., 26, 172-180 (2010).
36. Lal S, Szwergold BS, Taylor AH, Randall WC, Kappler F, Wells- Knecht K, Baynes JW, Brown TR. Metabolism of fructose- 3-phosphate in the diabetic rat lens. Arch. Biochem. Biophys., 318, 191-199 (1995).
37. Kador PF, Inoue J, Secchi EF, Lizak MJ, Rodriguez L, Mori K, Greentree W, Blessing K, Lackner PA, Sato S. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats. Exp. Eye Res., 67, 203-208 (1998).
38. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes, 55, 2757-2762 (2006).